ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Lymphovascular space invasion is associated with increased locoregional recurrence despite adjuvant radiotherapy in node-negative stage I-II endometrioid endometrial cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphovascular space invasion (LVSI) is an established prognostic factor in endometrial cancer; however, its biological and clinical impact in surgically staged early-stage cancer is unclear. This study aimed to evaluate the prognostic significance of substantial LVSI, defined per the WHO 2020 criteria as ≥5 vessel involvement, in stage I-II endometrioid endometrial cancer.
methodsWe retrospectively analyzed 215 patients with surgically staged, lymph-node negative, stage I-II endometrioid endometrial cancer. Substantial LVSI was defined as ≥5 vessel involvement; focal LVSI was classified as negative. Associations between LVSI and clinicopathological features, adjuvant treatment, and survival outcomes were evaluated. Survival analyses were performed using the Kaplan-Meier method and Cox proportional hazards models for overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS).
resultsSubstantial LVSI was identified in 6.5% of patients. Substantial LVSI-positive patients received adjuvant radiotherapy more frequently yet demonstrated significantly higher locoregional recurrence. In multivariate analysis, age and stage were independent predictors of OS and DFS; age alone was an independent predictor of DMFS. Substantial LVSI was the only independent prognostic factor for locoregional recurrence (HR: 4.531, 95%Cl 1.453-14.132, p = 0.009).
conclusionSubstantial LVSI is a strong predictor of locoregional recurrences in endometrial cancer, even in patients receiving adjuvant radiotherapy. These findings suggest that LVSI reflects an intrinsically aggressive tumor biology that current adjuvant treatment strategies may not fully control.
Indexed as
Identifiers
42517983What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.